Skip NavigationSkip to Content

Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers

  1. Author:
    Arndt, M. A. E.
    Krauss, R.
    Rybak, S. M.
  2. Author Address

    Univ Hosp Essen, Inst Immunol, D-45122 Essen, Germany. NCI, SAIC, Frederick, MD 21702 USA. NCI, Dev Therapeut Program, Frederick, MD 21702 USA Arndt, MAE, Univ Hosp Essen, Inst Immunol, Virchowstr 171, D-45122 Essen, Germany
    1. Year: 2004
    2. Date: DEC 17
  1. Journal: Febs Letters
    1. 578
    2. 3
    3. Pages: 257-261
  2. Type of Article: Article
  1. Abstract:

    By varying linker length and domain orientation three multivalent derivatives of a monovalent anti-CD22 single-chain fragment variable (scFv) antibody were generated. Shortening the linker of the V-H-V-L oriented scFv to 5 or 0 residues resulted in the formation of diabodies or a mixture of tetramers and trimers, respectively. Unexpectedly, a V-L-0-V-H scFv assembled to homogenous dimers, remained substantially more stable than the V-H-5-V-L diabody when incubated in human serum at 37 degreesC, and retained its dimeric state when concentrated up to 4 mg/ml. These properties suggest the V-L-0-V-H scFv could become an attractive vehicle for the selective delivery of multiple effector molecules to CD22(+) tumor cells. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved

    See More

External Sources

  1. DOI: 10.1016/j.febslet.2004.11.011
  2. WOS: 000225939900011

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel